Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) and/or previous AIDS) receiving the third do...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergori, Alessandra, Cozzi Lepri, Alessandro, Cicalini, Stefania, Matusali, Giulia, Bordoni, Veronica, Lanini, Simone, Meschi, Silvia, Iannazzo, Roberta, Mazzotta, Valentina, Colavita, Francesca, Mastrorosa, Ilaria, Cimini, Eleonora, Mariotti, Davide, De Pascale, Lydia, Marani, Alessandra, Gallì, Paola, Garbuglia, AnnaRosa, Castilletti, Concetta, Puro, Vincenzo, Agrati, Chiara, Girardi, Enrico, Vaia, Francesco, Antinori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395398/
https://www.ncbi.nlm.nih.gov/pubmed/35995780
http://dx.doi.org/10.1038/s41467-022-32263-7
Descripción
Sumario:In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm(3) (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log(2) difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.

Ejemplares similares